2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Neoplasms
7
Venous Thromboembolism
3
Venous Thrombosis
2
Thrombosis
2
Thromboembolism
2
Pulmonary Embolism
2
Prostatic Neoplasms
2
Urinary Tract Infections
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Sarcoma, Alveolar Soft Part
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Prostate Cancer Patients
1
Pneumonia
1
Pharmacokinetics of MDV3100
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Interventions
Dexamethasone
111
Cyclophosphamide
99
Melphalan
91
Bortezomib
69
Peripheral Blood Stem Cell Transplantation
64
Lenalidomide
58
fludarabine phosphate
56
Busulfan
54
Filgrastim
50
Tacrolimus
38
Antilymphocyte Serum
38
Thalidomide
36
Radiotherapy
36
Mycophenolic Acid
33
fludarabine
28
Cyclosporine
26
Methotrexate
25
Etoposide
22
Calcium Dobesilate
22
Whole-Body Irradiation
21
Prednisone
21
Methylprednisolone
20
sargramostim
19
pomalidomide
19
Granulocyte Colony-Stimulating Factor
18
carfilzomib
16
daratumumab
15
Cord Blood Stem Cell Transplantation
15
Carmustine
14
Rituximab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
Warfarin
×
Clear all
NCT00790842
2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2
Terminated
63 enrolled
14 charts